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The members of the RasGTPase superfamily are involved in various signaling networks responsible for fundamental cellular
processes. Their activity is determined by their guanine nucleotide-bound state. Recent evidence indicates that some of these
proteins may be regulated by redox agents. Reactive oxygen species (ROSs) and reactive nitrogen species (RNSs) have been
historically considered pathological agents which can react with and damage many biological macromolecules including DNA,
proteins, and lipids. However, a growing number of reports have suggested that the intracellular production of ROS is tightly
regulated and that these redox agents serve as signaling molecules being involved in a variety of cell signaling pathways. Numerous
observations have suggested that some Ras GTPases appear to regulate ROS production and that oxidants function as effector
molecules for the small GTPases, thus contributing to their overall biological function. Thus, redox agents may act both as
upstream regulators and as downstream effectors of Ras GTPases. Here we discuss current understanding concerning mechanisms
and physiopathological implications of the interplay between GTPases and redox agents.
1. Introduction
The Ras GTPase superfamily includes low molecular weight
GTP-binding and hydrolyzing (GTPases) proteins that act
as molecular switches by coupling extracellular signals to
different cellular responses, thus controlling cellular signal-
ing pathways responsible for growth, migration, adhesion,
cytoskeletal integrity, survival, and differentiation. The three
human Ras proteins, H-Ras, N-Ras, and K-Ras, are the
foundingmembers of this large superfamily of small GTPases
comprising over 150 human members with evolutionarily
conserved orthologs found in Drosophila, C. elegans, S. cere-
visiae, S. pombe, Dictyostelium, and plants. This superfamily
is divided into families and subfamilies on the basis of
sequence and functional similarities (Table 1). The fivemajor
families are Ras, Rho, Rab, Arf, and Ran [1]. In addition
to the different Ras isoforms, the Ras family includes Rap,
R-Ras, Ral, and Rheb proteins, also regulating signaling
networks. RhoGTPase family includes the well-characterized
family members Rac1, RhoA, and Cdc42, each of which
is associated with unique phenotypes and functions [2–4].
Rab proteins comprise the largest branch of superfamily
and regulate intracellular vesicular transport and trafficking
of proteins. Like the Rab proteins, Arf family proteins are
involved in regulation of vesicular transport. The Ran protein
is the most abundant small GTPase in the cell and is best
known for its function in nucleocytoplasmic transport of
both RNA and proteins [1].
Although being similar to the heterotrimeric G protein
α subunit in biochemical mechanism and function, Ras
GTPases function as monomeric GTP-binding proteins. The
functional diversity of these proteins is based on variations
in structure, posttranslational modifications that dictate spe-
cific subcellular localizations, and proteins that act as reg-
ulators and effectors [1, 5].
Signal transduction through Ras proteins occurs by re-
versible binding of GTP, while the inactive form is bound
to GDP. Switching between these two states is regulated by
three distinct types of protein modulator agents: Guanine
nucleotide Exchange Factors (GEFs) catalyze the exchange of
GDP with GTP to promote Ras activation, whereas GTPase-
Activating Proteins (GAPs) deactivate the Ras protein by
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Table 1: The Ras superfamily of small GTPases. The RasGTPase superfamily is divided into 9 families of small GTP-binding proteins on the
basis of sequence and functional similarities (modified from [7]).
Ras Rab Rho Sec Arf Rad Ran RheS Rit
H-Ras Rab1A RhoA N-Sec1 Arf1 Rad Ran/TC4 Rhes Rit
K-Ras Rab1B RhoB S-Sec1 Arf2 Gem Dexras1 Others Rin
N-Ras Rab2 RhoC Sec4 Arf3 Kir Others Ric
E-Ras Rab3A RhoD Sly1p Arf4 Rem1 Others
TC21 Rab3B RhoE Others Arf5 Rem2
R-Ras Rab4 Rnd1 Arf6 Others
M-Ras Rab5A Rnd2 Arf7
Rap1A Rab5B RhoG Others
Rap1B Rab6 Rac1
Rap2A Rab7 Rac2
Rap2B Rab8 Rac3
RalA Rab9 Cdc42
RalB Rab10 TC10
Others Others TTF
Others
stimulating hydrolysis of bound GTP to GDP. Deactivation
can also be achieved by association with Guanine Nucleotide
Dissociation Inhibitors (GDIs), which prevent membrane
association, and GDP dissociation. All of these regulatory
proteins are themselves affected by diverse upstream signals,
which serve to activate or inactivate Ras GTPase signaling
pathways. The transition of Ras proteins between the GDP-
and GTP-bound states is accompanied by a conformational
change that greatly enhances their affinity for downstream
effectors [6]. The interaction between the active GTP-bound
GTPase and the effector molecule leads to activation of
downstream signal transduction pathways.
In addition to these protein regulatory factors, many of
the Ras superfamily small GTPases have been shown to be
redox sensitive, and their known conserved redox-sensitive
sequences have been termed the NKCD, GXXXXGK(S/T)C,
and CGNKXD motifs. The action of redox agents on these
redox-sensitive GTPases is similar to that of guanine nu-
cleotide exchange factors in that they perturb GTPase nu-
cleotide-binding interactions that result in the enhancement
of the guanine nucleotide exchange of small GTPases [7].
For many years, the generation of intracellular redox
agents such as reactive oxygen species (ROS) and reactive ni-
trogen species (RNS) was viewed solely as the unregulated
by-product of aerobic metabolism and other enzymatic
processes, and redox agents have been historically considered
pathological agents which can react with and damage many
biological macromolecules including DNA, proteins, and
lipids. However, over the last years a growing number of
reports have suggested that mammalian cells can rapidly
respond to ligand stimulation with a change in intracellular
ROS thus indicating that the production of intracellular
ROS is tightly regulated and that these redox agents serve as
intracellular signaling molecules being involved in a variety
of cell signaling pathways, including growth factor signaling
[8, 9], inflammation [10], engagement of integrins [11,
12], and adhesion to extracellular matrix [13]. The precise
means of regulation is not completely understood. However,
numerous observations have suggested that the Ras GTPases
appear to regulate ROS production and that oxidants func-
tion as effector molecules for the small GTPases, thus con-
tributing to their overall biological function [14].
Here we discuss current understanding concerning the
interplay between GTPases and redox agents. The discussion
also takes into account pathological implications of alter-
ations of both ROS regulation by small GTPases and small
GTPases regulation by ROS.
2. ROS Regulation by RasGTPases
Among the major source of ROS, NADPH oxidases have
been demonstrated to play a fundamental role in the com-
partmentalization of ROS production and redox signaling
[15]. Besides NADPH oxidase, an important role in the
spatio-temporal regulation of ROS production is also played
by enzymes involved in arachidonic acid (AA) metabolism,
such as phospholipase A2 (PLA2), lipooxygenases (LOXs),
and cyclooxygenases (COXs), suggesting that a complex reg-
ulatory network may take place for proper modulation of re-
dox signaling [16].
The NADPH oxidase (NOX) complex was originally
identified in phagocytic leukocytes as an enzymatic defense
system against infections required for the oxidative burst-
dependent microbial killing [17–19]. It is composed of
membrane-associated and cytosolic components, which
assembly to form the active NOX enzymatic complex in
response to appropriate stimuli. Specifically, this complex
consists of membrane-associated cytochrome b558, com-
prising the catalytic gp91phox (also known as NOX2) and
regulatory p22phox subunits, and four cytosolic regulatory
components, including p40phox, p47phox, p67phox, and the
small GTPase Rac1 [17]. The neutrophil expresses two
different Rac isoforms, including the phagocyte-specific
Rac2 and the more ubiquitously expressed Rac1. Detailed
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molecular analysis has revealed that Rac proteins function as
a necessary switch for ROS generation and that the protein
is recruited to the membrane following neutrophil activation
where it can bind to both p67phox and gp91phox [20].
Many evidences suggest that certain aspects of neutrophil
biology appear to be conserved in the ROS signaling of non-
phagocytic cells. In particular, homologues of the NADPH
oxidase were found in vascular endothelial cells and smooth
muscle cells, as well as in other normal or transformed cells
such as colon cancer or melanoma [21]. Several isoforms of
the catalytic NOX2 protein were identified, including NOX1,
NOX3, NOX4, and NOX5, and shown to localize in prox-
imity of specific redox-sensitive molecular targets within dis-
crete subcellular compartments, thereby facilitating the com-
partmentalization of redox signaling [15]. In addition, the
expression of a constitutively activated form of Rac1 was
noted to increase the basal level of hydrogen peroxide in
immortalized fibroblasts [22] as well as in certain trans-
formed cell lines [23], while the expression of a dominant
negative form of Rac1 was shown to inhibit the production
of ROS following addition of various ligands [22]. These data
suggest that a Rac-regulated oxidase exists in a wide range of
cell types and participates in normal signal transduction.
It has been shown that NOX1 constitutively binds the
RacGEF βPIX, and the interaction is caused by growth factor
stimulation [24]. This and previous studies [25] also support
a pathway where ligand addition results in the sequential
activation of phosphatidylinositol 3-kinase (PI3K), which in
turn generates lipid products that can activate GEFs through
the PH (pleckstin homology) domain present within the
exchange factors. Activation of the GEF leads to increased
Rac activity that is presumed to directly stimulate NOX [14].
The hypothesis that ROS generation is regulated by Rac
and the role of ROS as specific effector molecules that act
downstream of Rac is supported by several evidences. In a
recent paper there has been shown a role of Rac-regulated
ROS in the crosstalk between G-protein-coupled receptors
(GPCRs) and the JAK/STAT pathway [26], while different
studies support a role of Rac1 as a crucial, common upstream
mediator of ROS production in integrin-mediated outside-in
signaling [11–13, 16, 27].
Several evidences have implicated ROS in the integration
of signals from VEGF and Rac to regulate the integrity of
the endothelial barrier [22, 28–32]. Further studies demon-
strated that the VEGF-dependent phosphorylation of VE-
cadherin and β-catenin are dependent on Rac and ROS
and result in decreased junctional integrity and enhanced
vascular permeability [33, 34].
In addition to NADPH oxidase, Rac1 has been demon-
strated to act upstream of AA-metabolizing enzymes, such as
PLA2 [35, 36], 5-LOX [13, 26, 27], and COX-2 [37], whereas
many reports show that AA metabolism modulates NADPH
oxidase and mitochondrial ROS production [16].
Another aspect of oxidant signaling derived from the
initial observation that Rac proteins regulate ROS levels is
the demonstration of redox-dependent crosstalk between
different small GTPase family members.
ROS production is apparently an essential component in
signaling cascades that mediate Rac1/p190RhoGAP-induced
downregulation of RhoA and concomitant formation of
membrane ruffles and integrin-mediated cell spreading. The
pathway linking generation of ROS to downregulation of
Rho involves inhibition of the low-molecular-weight pro-
tein tyrosine phosphatase (LMW-PTP) and a consequent
increase in the activation by phosphorylation of the Rho
inhibitor p190Rho-GAP [38]. It has been shown that
ROS production causes p190RhoGAP translocation to the
adherens junctions (AJs), where it binds p120ctn, and sub-
sequently inhibits local Rho activity [39]. It thus plays a role
in the stabilization of cell-cell contacts [34].
These findings suggest that Rac1 downregulates Rho and
stress fiber formation in a redox-dependent manner and
define amechanism for the coupling of changes in cellular re-
dox state to the control of actin cytoskeleton rearrangements
by Rho GTPases.
In addition to Rac, the production of ROS by nonphago-
cytic cell types stimulated by growth factors or cytokines
includes the participation of p21Ras [22]. Fibroblasts ex-
pressing constitutively active mutants of both Rac and Ras
produce high levels of ROS associated with a high rate of
proliferation. In the same study experimental evidence was
provided suggesting that Rac is positioned downstream to
Ras. Similar overexpression of Ras in other cell types such as
keratinocytes [40] and epithelial cells [41] also demonstrated
an increase in basal ROS levels. The pathway by which Ras
regulates the levels of ROS remains incompletely understood.
It has been shown that in some cells it proceeds through
a PI3K and Rac-dependent pathway [25] leading to the
regulation of a NOX-dependent oxidase. In other cell types
the source of Ras-induced ROS appears to be linked to the
mitochondria [42].
Mitochondria have the highest levels of antioxidants in
the cell and play an important role in the maintenance of
cellular redox status, thereby acting as a ROS and redox sink
and limiting NADPH oxidase activity. However, mitochon-
dria are not only a target for ROS produced by NADPH
oxidase but also a significant source of ROS, which under
certain conditions may stimulate NADPH oxidases. Many
findings indicate the existence of a bidirectional signaling
crosstalk between mitochondria and NADPH oxidase, where
small GTPases can orchestrate a complex web of regulation
for ROS production [43–45].
Indeed, in integrin signaling, the regulation of mitochon-
dria by both Rac and RhoA appears to be related to their
ability to alter intracellular ROS [12].
It has been shown that Nerve Growth Factor- (NGF-)
induced differentiation of PC12 cells is mediated by signif-
icant alteration of mitochondrial metabolism by reducing
mitochondrial-produced ROS and stabilizing the electro-
chemical gradient. This is accomplished by stimulation of
mitochondrial manganese superoxide dismutase (MnSOD)
via Ki-Ras and ERK1/2 [46].
Thus ROS produced by small GTPases could regulate
mitochondrial properties, including the overall metabolic
rate and the generation of mitochondrial oxidants with im-
portant signaling functions within the cell [14].
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3. RasGTPase Regulation by ROS
Although several studies implicate RasGTPases in the pro-
duction and regulation of intracellular ROS, many evidences
indicate that Ras proteins can also be direct targets of ROS.
Similar to the action of GEFs, various redox agents, including
both ROS and RNS, have been shown to stimulate Ras
guanine nucleotide dissociation in vitro and upregulate Ras
function in vivo.
Lander and coworkers showed for the first time that NO
is able to activate Ras by promoting RasGDP dissociation
in vitro, GTP binding to Ras in vivo, and stimulation of
pathways downstream to Ras [47–54]. The target site of
NO-mediated guanine nucleotide dissociation on Ras is
Cys118, which is located in the nucleotide-binding NKCD
motif [49, 50, 54, 55]. Further studies indicated that •NO2,
a reaction product of NO with O2, reacts with the Ras
Cys118 thiol to induce a radical-based process leading to
stimulation of nucleotide exchange on Ras [56, 57]. In
addition to NO, O2
•− showed to be able to facilitate
guanine nucleotide dissociation from Ras as well as the Ras-
related GTPase Rap1A. The molecular mechanism of O2
•−-
mediated guanine nucleotide dissociation is similar to that of
the NO/O2-mediated guanine nucleotide dissociation [58].
The redox-sensitive NKCD motif has been found within the
Ras subfamily of GTPases such as H, N, K, and E-Ras as well
as in Rap1A [7].
Redox-active motifs were afterwards found to be present
in other Ras superfamily GTPases, suggesting that redox reg-
ulation of GTPase signaling is more widespread that previ-
ously envisioned [59].
The GXXXXGK(S/T)C redox-sensitive motif, located in
the phosphoryl-binding loop important for redox-mediated
regulation of guanine nucleotide exchange activity in vitro,
was identified and characterized in the Rho family GTPases.
This motif contains a redox-sensitive cysteine (Cys18, Rac1
numbering) at the C-terminus and it is conserved in almost
half of Rho family GTPases such as Rac1 (and its isoforms
Rac2 and 3), Cdc42, and RhoA (and its isoforms RhoB
and C) [59, 60]. The radical-based molecular mechanism of
Rho GTPase guanine nucleotide exchange appears similar in
nature to the mechanism characterized for Ras GTPases.
An in vivo study aimed to analyze the effect of exogenous
and endogenous ROS on the activation of RhoA in fibroblasts
was performed by Aghajanian and coworkers [61]. This study
showed that RhoA can be directly activated by ROS in cells
by oxidative modification of critical Cys residues within the
redox-active motif, and that ROS-mediated activation of
RhoA can induce cytoskeletal rearrangement, thus support-
ing the existence of a novel mechanism of regulating GTPase
signaling cascades, independent to classical regulation by
GEFs and GAPs, that can affect cytoskeletal dynamics [61].
A number of Rab proteins also have the
GXXXXGK(S/T)C motif (Rab1B, Rab2A/B, Rab4A/B,
Rab14, Rab15, Rab19, and Sec4). Intriguingly, many Rab
GTPases (Rab1A, Rab8A/B, Rab10, and RAb13) possess both
the NKCD and GXXXXGK(S/T)C motifs, whereas some Rab
proteins (Rab3A/B/C/D, Rab 7, Rab22, and Rab38) possess
only the NKCD motif [7].
A CGNKXD redox-sensitive motif was found in Ran pro-
tein [62]; this motif contains a redox-sensitive cysteine,
Cys120, at the N-terminal. In addition to this CGNKXD
motif, Ran possesses an additional redox-sensitive cysteine
Cys85 (Ran numbering). This type of redox center is also
conserved in Dexras1 and Rhe proteins as well as in some
Rab GTPases [62].
Although redox regulation of the members of Rab and
Ran families has been recently discovered, its physiological
relevance and pathological consequences linked to the mis-
regulation of redox signaling associated with these redox
sensitive small GTPases have not yet been explored [7].
4. Pathological Implications of the Interplay
between Small GTPases and ROS
Over the past several years, it has become clear that ROSs
play an important role in physiological processes like cell
differentiation, proliferation, migration, and vasodilatation.
On the other hand, production of ROS “in the wrong place at
the wrong time” results in oxidative stress leading to cellular
dysfunction and apoptosis, which contributes to different
pathologies like atherosclerosis, heart failure, hypertension,
ischemia/reperfusion injury, cancer, aging, and neurodegen-
eration [40].
There is a vast body of literature that links vascular
ROS production to cardiovascular disease [63]. Vascular ROS
production as well as Rac1 activation has been associated
with hypertrophy and smooth muscle cell proliferation,
endothelial dysfunction as well as endothelial cell migration,
hypertension inflammation, and atherosclerosis [64–67].
Vascular hypertrophy has been ascribed to the effects of
various receptor agonists, including Angiotensin II (Ang
II), which induces ROS production in VSMCs in a Rac1-
dependent fashion [68]. Recent studies showed that this
Ang II-induced ROS production also requires the membrane
adapter caveolin, which is involved in Rac1 activation [69,
70], and the lipid kinase PI3K-γ [68, 71].
Ischemia/reperfusion (I/R) injury is also associated with
ROS production. This is a clinically relevant problem oc-
curring as damage to the myocardium following blood res-
toration after a critical period of coronary occlusion. It is
well known that immediately following the reinstitution of
oxygenated blood into ischemic tissue, there is a rapid burst
of ROS, but the molecular basis and source of this process
are not yet convincingly identified [14, 72]. However, both
in vitro and in vivo experiments [73, 74] have suggested that
Rac1 plays a dominant role in ROS generation after I/R, and
it activates the nuclear factor NF-κB and stimulates mRNA
expression of several inflammatory genes, such as TNF-α and
iNOS in the liver, leading to massive hepatocyte necrosis.
Thus, efforts aimed at inhibiting Rac protein function could
be useful therapeutic strategies in a variety of clinical settings
in which there is concern about the potential harmful effects
of I/R injury [73, 74].
Data from the literature suggest that ROS and RhoA
activation are associated to airway smooth muscle contrac-
tility [75–77]; it has been shown that oxidative stress with
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H2O2 leads to airway smooth muscle contraction mediated
by increases in intracellular Ca2+ concentration and the
Rho/Rho kinase pathway [77].
Both ROS and Rho/Rho kinase have been suggested to
play important roles in vasoconstriction and may contribute
to the pathogenesis of hypertension in experimental animals
and humans. Jin and coworkers demonstrated the direct
activation of the Rho/Rho kinase signaling pathway by ROS
in rat aorta, suggesting an important role for ROS-mediated
Rho/Rho kinase activation in vasoconstriction [78].
As previously discussed, Aghajanian and coworkers pro-
posed a novel mechanism for the regulation of RhoA in cells
by ROS that allows predicting that ROS may directly activate
Rho signaling in smoothmuscle and in the endothelium thus
affecting vascular permeability. This mechanism of regula-
tion, which is independent of classical regulatory proteins,
may be particularly relevant in pathological conditions where
ROSs are generated and the cellular redox-balance altered,
such as in asthma and I/R injury [62].
It is well known that activated Ras signaling contributes
to oncogenic transformation by providing molecular signals
that promote cell proliferation, obstruct cell death, inhibit
cellular differentiation, and induce angiogenesis [79]. Sig-
naling pathways starting from activated Ras and resulting in
mitochondrial ROS production and downstream signaling
regulation have been the subject of several recent interesting
studies, and different mechanisms have been proposed to
elucidate the role of mitochondrial respiration in cancer.
It has been shown that the activation of K-Ras(G12V)
causes modifications in mitochondrial metabolism finalized
to support growth under hypoxic conditions, and leading
to increased generation of ROS [80]. The major source
of ROS generation required for KRas-induced anchorage-
independent growth is the Qo site of mitochondrial complex
III [81]. Thus mitochondrial dysfunction appears to be an
important mechanism by which K-Ras(G12V) causes met-
abolic changes and ROS stress in cancer cells and promotes
tumor development [80].
Mitochondrial dysfunction and ROS production medi-
ated by activation of Ras, Myc, and p53 produce downstream
signaling (e.g., NFκB, STAT3, etc.) that are crucial in cancer-
related inflammation. Different inflammation-associated
cancers resulting from signaling pathways coordinated at
the mitochondrial level have been identified that may prove
useful for developing innovative strategies for both cancer
prevention and cancer treatment [82].
Several studies suggest that autophagy may be important
in the regulation of cancer development and progression and
in determining the response of tumor cells to anticancer
therapy [83]. A recent paper shows that autophagy is
associated with the malignant transformation of mammalian
cells induced by K-Ras and that ROSs are involved as sig-
naling molecules in K-Ras(G12V)-induced autophagy. The
increase in intracellular ROS produced in response to on-
cogenic K-Ras involves p38 MAPK signaling and leads to
JNK activation. JNK acts downstream of ROS and plays a
causal role in autophagy induction through upregulation of
autophagy-specific genes 5 and 7 (ATG5 and ATG7) [84].
As mitochondria sustain viability of Ras-expressing cells in
starvation, autophagy is required to maintain the pool of
functional mitochondria necessary to support growth of Ras-
driven tumors [85]. These findings provide new insights
into the relationship between autophagy and oncogenesis
and suggest that targeting autophagy and mitochondrial
metabolism are valuable new approaches to treat cancers
with Ras mutations.
Oncogenic activation of the H-Ras gene has been found
in more than 35% of patients with urothelial carcinomas
[86]. It has been recently shown that in addition to tu-
morigenic ability, oncogenic H-Ras possesses a novel proap-
optotic activity to facilitate the induction of apoptosis by
histone deacetilase inhibitors (HDACIs), a new class of an-
ticancer agents characterized by high cytotoxicity toward
transformed cells [87]. Expression of oncogenic H-Ras in
human bladder tumor J82 cells and treatment of cells with
the HDACI, FK228, sinergistically induce the ERK pathway,
resulting in differentially increased NOX-1 elevation and
ROS production, leading to differential activation of caspases
and cell death [88–90]. Thus, in addition to its well-known
role in mediating mitogenic signals for cell proliferation
and transformation, the ERK pathway plays an essential
role in mediating apoptotic signals induced by HDACIs
through induction of NOX-1 elevation to ROS production
and caspase activation for inducing cell death. In addition,
expression of oncogenic H-Ras in J82 cells also results in an
increased susceptibility to exogenous H2O2 for inducing cas-
pase activation and apoptosis [88]. Further studies revealed
that FK228 combined with exogenous H2O2 cooperatively
induces activation of MEK1/2 and ERK1/2 to increase NOX-
1 elevation, intracellular ROS production, caspase activa-
tion, and cell death. Expression of oncogenic H-Ras sig-
nificantly increases these FK288- and exogenous H2O2-
induced effects. Oncogenic H-Ras-increased susceptibility to
FK228 could be alternatively achieved by additional treat-
ment with exogenous H2O2. These findings have important
and useful implications as combined use of HDACIs with
ROS-generating agents may apply to therapeutic strategies to
preferentially kill malignant cells with or without oncogenic
H-Ras activation [91].
Due to the crucial role played by Ras in many cellular
signaling cascades, diseases relevant to dysregulation of redox
signaling often result in deregulation of Ras-dependent cel-
lular signaling events. Since the first identification of the
redox-sensitive NKCDmotif of Ras [51], considerable patho-
physiological data are available, including some bearing
directly on the relevance of redox-mediated misregulation of
the Ras NKCD motif to certain diseases [7]. Rap1A, another
reprehensive protein that possesses the NKCD-motif, is a reg-
ulator of NAD(P)H oxidase. However, a pathophysiological
outcome associated with the misregulation of Rap1A redox
signaling has not been clearly investigated [7].
Cancer is one of the most prevalent disorders caused by
misregulation of Ras activity by a redox agent. Numerous
studies show that cancers, to a large extent, are induced
by misregulation of Ras redox signaling combined with an
alteration of Ras downstream cellular transduction cascades.
As with cancers, many cardiovascular and neuronal disorders
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appear to be the result of dysregulation of various cellular
signaling events via the redox-sensitive Ras (for a deeper
investigation see [7]).
The misregulation of the redox signaling of Ras with
its downstream cascades also has been linked to various
disorders linked with immune and embryo developments.
The Ras-dependent activation of Raf also leads to stimulation
of a phosphorylation of Ets-like protein-1 and tumor necro-
sis factor-α messenger RNA induction; both actions suggest
that NO, through the Ras-dependent Raf-MEK1/2-ERK1/2
pathway, modulates a host’s defenses and the inflammation
of T lymphocytes [92]. ROS-mediated signaling via Ras, NF-
κB, and related transducers may link to embryopathies [93].
5. Concluding Remarks
Although, for many years, the generation of intracellular
redox agents was viewed solely as the unregulated by-product
of aerobic metabolism and other enzymatic processes, over
the last years a growing number of reports have suggested
that the production of intracellular ROS is tightly regulated
and that these redox agents serve as intracellular signaling
molecules being involved in a variety of cell signaling path-
ways. Here we have reviewed studies reporting that mem-
bers of the RasGTPase superfamily are able to regulate in-
tracellular ROS production, and that the production of
ROS by small GTPases is an important aspect of the
function of these monomeric G-proteins. In addition, the
functional cross-talk between some different RasGTPase
family members (see Rac1 and RhoA) appears strictly related
to redox signaling. Finally, due to the presence of conserved
redox-sensitive sequences, many of the Ras superfamily small
GTPases have been shown to be targets of ROS regulation.
Thus, redox agents, as upstream regulators and/or down-
stream effectors of redox-sensitive RasGTPases, strongly con-
tribute to their overall biological function playing a key role
in various cellular signaling events. Dysregulation of small
GTPases by redox agents or dysregulation of redox signaling
by small GTPases may significantly alter cellular signaling
pathways and lead to the pathological state.
Given the prominent role the RasGTPase family mem-
bers play in regulating fundamental cell processes like
growth, migration, adhesion, cytoskeletal integrity, survival,
and differentiation, the comprehension of molecular mech-
anisms of the interplay between small GTPases and ROS
may strongly help to clarify how redox agents contribute to
physiological and pathological cellular events and provide
novel strategies for treatment of many pathological condi-
tions where both RasGTPases and oxidative stress play a role.
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